SITE013-0183

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE013 (USA) (Dr. Clarke) · consented 2022-10-07

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

severe serious assessed 2026-08-18

Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-25 (study day 9); relationship: N; serious criteria: life-threatening

mild assessed 2026-08-18

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-11-08 (study day 23); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-16 (study day 31); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-09 (study day 54); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-17 (study day 62); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-23 (study day 68); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 72); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.